TYKERB in combination with capecitabine slowed the progression of HER2+ metastatic breast cancer
The primary measurement of treatment effectiveness in the TYKERB® (lapatinib) tablets plus capecitabine study was time to progression.
- Progression means the tumors have grown, spread, or returned. Time to progression is how much time passed until the patient showed progression or died from breast cancer. Median time to progression is the time when at least half of the patients in the study reached this time point
- Two groups of medical experts analyzed the study results for the time to progression. The following two graphs show their findings
Independent experts found longer time to progression with TYKERB plus capecitabine compared with capecitabine alone
- In review 1, the median time to progression was 27.1 weeks for women who took TYKERB
- This was 8.5 weeks longer than for women who took capecitabine alone
Study experts also confirmed benefit of combination therapy
- In review 2, the median time to progression was 23.9 weeks for women who took TYKERB
- This was 5.6 weeks longer than for women who took capecitabine alone
NOTE: Results have not shown an increase in overall survival.
Important Safety Information
Do not take TYKERB if you are allergic to any of the ingredients in TYKERB.
It is not known if TYKERB is safe and effective in children.
Before taking TYKERB, tell your doctor if you have heart problems. Some people may develop heart problems while taking TYKERB, including decreased pumping of blood from the heart and an abnormal heartbeat. Call your doctor right away if you feel like your heart is pounding or racing; if you are dizzy, tired, or light-headed; or if you are short of breath. Your doctor should check your heart before and during treatment with TYKERB.
TYKERB plus capecitabine reduced tumors in more women than in those who took capecitabine alone
A second measurement of effectiveness in the study was response rate. Response is when the treatment has reduced the size or number of tumors.
- Response rate is the percentage of patients in the treatment group who had a response.
Two groups of medical experts analyzed the study results for response rate. The following two graphs show their findings.
- In review 1, 23.7% of women (or nearly 1 in 4) who took TYKERB plus capecitabine had a response
- Only 13.9% of women (or nearly 1 in 7) who took capecitabine alone had a response to treatment
- In review 2, 31.8% of women (or nearly 1 in 3) who took TYKERB plus capecitabine responded
- Only 17.4% of women (or about 1 in 6) who took capecitabine alone responded to treatment